Karl Tryggvason, MD, PhD, a citizen of Iceland and Sweden, got his MD training at the Univerisity of Oulu in Finland. He is a specialist in clinical chemistry (clinical pathology). He has spent 4 years as postdoc and visiting professor in the USA, and was professor of biochemistry at the University of Oulu prior to his move to Karolinska Institutet in 1995. He is currently professor of medical chemistry at the Department of Medical Chemistry and Biophysics (MBB) and a member of the Nobel Assembly for physiology or medicine.
Karl Tryggvason has made broad contributions to the characterization of the structure and biology of basement membranes and has identified the molecular basis of five genetic diseases, two of which are kidney diseases. He has a research staff of about 30 persons from numerous countries.Tryggvason is cofounder of BioStratum Inc. and NephroGenex Inc.